All Merck & Co articles
-
OpinionThe shadow of drug resistance
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?
-
BusinessCovid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
-
BusinessNew antiviral impresses against Covid-19
Merck & Co and Ridgeback’s molnupiravir reduces risk of hospitalisation and death, and may work against other coronaviruses
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
BusinessTrump coaxes big promises from big pharma
Several drug industry giants are now pledging to freeze price increases in the US, but some suggest the movement is a publicity stunt or worse
-
ResearchRobots explore chemistry’s dark spaces
Thousands of nanoscale experiments create map of reactions that don’t work
-
BusinessChemist caught stealing and dumping cyanide
Merck & Co senior analytical chemist arrested for stealing and then dumping highly toxic substance down a curbside drain
-
ResearchMachine learning triumphs in tough cross coupling challenge
5000 nanoscale experiments teach algorithm how to predict outcomes of reactions in the presence of inhibitors
-
BusinessMerck & Co and Qiagen to build UK research hubs
Almost 2000 jobs to be created at research centres in Manchester and London
-
ResearchWhat’s left isn’t always right in total synthesis
Scientists turn detective to solve a decade-old stereochemical enigma
-
BusinessChemical and pharma bosses quit US manufacturing council
President Trump disbands the group after multiple advisers resign in protest against his stance on racism
-
OpinionMaking enough of a difference
What if the needle in the drug development haystack ends up being too small to be useful?
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
ResearchCatalyst puts chiral twist on phosphorus drugs
Simple molecule overcomes headache of phosphorus stereochemistry in antiviral drug synthesis
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessNovartis consolidates research sites
Company will close research sites in China and Switzerland, and relocate another from Singapore to US
-
NewsPharma giants commit to tackling antimicrobial resistance
Plan to tackle superbugs includes changes to manufacturing and sales incentives
-
BusinessJudge voids Merck & Co’s $200m patent claim
‘Serious misconduct’ kills case over Gilead’s hepatitis C drugs
-
Business
Merck & Co to buy Afferent for neurology drugs
Deal worth up to $1.25bn includes drug candidate for chronic coughs
-
BusinessGilead loses to Merck & Co in hepatitis C drug dispute
US court upholds Merck’s claim to patents related to blockbuster drugs